By acquiring Crinetics Pharmaceuticals, Vertex is staking its place alongside other big biotechs such as Gilead, Regeneron and Biogen.
Vertex Pharmaceuticals’ $10 billion acquisition of an endocrinology startup represents the company’s clearest and boldest step toward the upper echelon of the biopharma industry.
Long …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V
Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why - Crinetics Pharmaceuticals (NASDAQ:C
Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket - Riv
Compass says depression drug has long-lasting benefits
Patent cliff fuels Novartis' $1.5bn swoop for London biotech
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10…
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid…
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and…
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder,…
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker…
Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to…
